In this issue:
Antitumour activity and safety of CMG901
The FRACTION-GC trial
Can regorafenib improve OS
Camrelizumab plus rivoceranib and SOX
Nivolumab/ipilimumab versus chemotherapy
Prediction model for long-term survival
Postoperative surgical outcomes after total gastrectomy
Tolerability of T-DXd
Please login below to download this issue (PDF)